OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corpo...

SAN DIEGO, Feb. 8, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present new clinical data on ImmunoPulse^® IL-12, its lead program focused on oncology, at the upcoming 2017 American Association for Cancer Research & Society for Immunotherapy of Cancer (ASCO-SITC) Clinical Immuno-Oncology Symposium.  In addition, Punit Dhillon, President & CEO, will present a corporate overview at two investment conferences in February, including: the 19^th Annual BIO CEO & Investor Conference and Source Capital Group's 2017 Disruptive Growth & Healthcare Conference.

2017 ASCO-SITC Clinical Immuno-Oncology Symposium 
Dr. Alain Algazi, Associate Clinical Instructor, Department of Medicine (Hematology/Oncology), at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, will present an oral and poster presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium to be held on February 23-24, 2017, in Orlando, FL.

Details of the presentation are as follows:

Abstract Title: Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12) (Abstract ID #78) 
Session Title: Activating the Immune System-New Clinical Approaches 
Date and Time: February 23, 2017 at 11:30 a.m. – 1:00 p.m. (poster) & 3:30 p.m. – 5:00 p.m. EST (oral) 
Location: Hyatt Regency Orlando

Further details on this ASCO-SITC oral and poster presentation will be provided in upcoming Company communications. For more information about this symposium, please visit: http://immunosym.org/

The 19^th Annual BIO CEO & Investor Conference
Mr. Dhillon will present a corporate overview at The 19^th Annual BIO CEO & Investor Conference on February 14 at 3:00 p.m. EST at The Waldorf Astoria in New York City.

To view to the live webcast, please access the following link at the time of the presentation: http://www.veracast.com/webcasts/bio/ceoinvestor2017/98226117037.cfm. An archived version of the webcast will be available for 90 days on OncoSec's website: http://www.oncosec.com.

For more information about this conference, please visit: https://www.bio.org/events/bio-ceo-investor-conference

Source Capital Group's 2017 Disruptive Growth & Healthcare Conference 
Mr. Dhillon will present a corporate overview at Source Capital Group's 2017 Disruptive Growth & Healthcare Conference on February 15 at 3:00 p.m. EST at Convene in New York City.

For more information about this conference, please visit: www.DisruptNYC.com.

About OncoSec Medical Incorporated 
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer.  ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.

CONTACT: 
Punit Dhillon 
President & Chief Executive Officer  
OncoSec Medical Incorporated 
855-662-6732 
[e-mail]

Media: 
Laura Radocaj 
Dian Griesel Int'l. 
212-825-3210

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-present-new-clinical-data-from-phase-2-combination-study-at-asco-sitc-clinical-immuno-oncology-symposium-and-corporate-updates-at-two-investment-conferences-in-february-300403831.html

SOURCE OncoSec Medical Incorporated

Copyright 2017 PR Newswire